Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 17;14(2):e22317.
doi: 10.7759/cureus.22317. eCollection 2022 Feb.

The Association Between Anti-Thyroid Peroxidase Antibody and Dyslipidemia in Subclinical Hypothyroidism Among the Rural Population of Central India

Manoj Kumar  1 , Dheeraj Dheeraj  2 , Ravi Kant  2 , Ashok Kumar  1
Affiliations

The Association Between Anti-Thyroid Peroxidase Antibody and Dyslipidemia in Subclinical Hypothyroidism Among the Rural Population of Central India

Manoj Kumar et al. Cureus. .

Abstract

Objective In this study, we aimed to determine the association between anti-thyroid peroxidase (anti-TPO) antibody and dyslipidemia in subclinical hypothyroidism (SCH). Materials and methods We conducted a cross-sectional case-control study in the department of medicine at a tertiary care teaching hospital in central India. The study consisted of 150 patients (75 cases and 75 controls) who fulfilled the inclusion and exclusion criteria. Results The study showed that serum cholesterol was high in 23.1% of cases in the negative anti-TPO antibody SCH sub-group and 88.7% of cases in the positive anti-TPO antibody SCH sub-group (p<0.001). Serum triglyceride (TG) levels were high in 61.5% of cases in the negative anti-TPO antibody SCH sub-group and 90.3% of cases in the positive anti-TPO antibody SCH sub-group (p=0.008). Serum high-density lipoproteins (HDL) were low in 15.4% of cases in the negative anti-TPO antibody SCH sub-group and 24.2% of cases in the positive anti-TPO antibody SCH sub-group (p=0.490). Serum low-density lipoproteins (LDL) were high in 61.5% of cases in the negative anti-TPO antibody SCH sub-group and 90.3% of cases in the positive anti-TPO antibody SCH sub-group (p=0.008). Serum very-low-density lipoproteins (VLDL) were high in 84.6% of cases in the negative anti-TPO antibody SCH sub-group and 83.9% of cases in the positive anti-TPO antibody SCH sub-group (p=0.947). Based on our findings, 82.8% of participants with negative anti-TPO antibodies had normal serum LDL levels, while 11.1% of participants with positive anti-TPO antibodies had normal LDL levels (p<0.001). The study also showed that elevated serum LDL was present in 17.2% of participants with negative anti-TPO antibody levels and 88.9% of participants with positive anti-TPO antibodies (p<0.001). The study showed a correlation coefficient of 0.0432 between serum TG and anti-TPO antibody levels (p<0.001). Conclusion Our findings showed an increased incidence of dyslipidemia in SCH patients with positive anti-TPO antibodies. SCH with positive anti-TPO antibody is significantly associated with elevated serum total cholesterol (TC) levels, serum TG levels, and serum LDL levels. Hence, early screening and diagnosis of dyslipidemia are crucial to prevent cardiovascular morbidity and mortality in SCH patients with positive anti-TPO antibodies.

Keywords: cardiovascular prevention; dyslipidemia; lipid profiles; subclinical hypothryroidism; thyroid disorder; thyroid peroxidase antibodies.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Study flow chart
TPO: thyroid peroxidase
Figure 2
Figure 2. Correlation between anti-TPO antibody and triglyceride
TPO: thyroid peroxidase
Figure 3
Figure 3. Correlation between lipid profile and anti-TPO antibodies
TPO: thyroid peroxidase; S. Chol: serum cholesterol; S.TG: serum triglyceride: HDL: high-density lipoprotein; LDL: low-density lipoprotein; VLDL: very-low-density lipoprotein
See this image and copyright information in PMC

References

    1. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Garber JR, Cobin RH, Gharib H, et al. Thyroid. 2012;22:1200–1235. - PubMed
    1. LDL/HDL-changes in subclinical hypothyroidism: possible risk factors for coronary heart disease. Althaus BU, Staub JJ, Ryff-De Lèche A, Oberhänsli A, Stähelin HB. Clin Endocrinol (Oxf) 1988;28:157–163. - PubMed
    1. Subclinical hypothyroidism and the risk of hypercholesterolemia. Hueston WJ, Pearson WS. Ann Fam Med. 2004;2:351–355. - PMC - PubMed
    1. Association of thyroid peroxidase antibody and dyslipidemia in subclinical hypothyroidism. Srivastava VK, Singh H. J Family Med Prim Care. 2017;6:63–68. - PMC - PubMed
    1. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Fedder DO, Koro CE, L'Italien GJ. Circulation. 2002;105:152–156. - PubMed

LinkOut - more resources